EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparing cost-effectiveness of short-course regimens for drug-resistant tuberculosis treatment in India

Malaisamy Muniyandi iD, Balaji Ramraj, Sathishkumar Vadamalai, Sahil Abdul Salam, Bella Devaleenal, Jyoti Jaju, Chandrasekaran Padmapriyadarsini

International Journal of Technology Assessment in Health Care · 2025 · 41 (1)

DOI: 10.1017/s0266462325100329 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Technology Assessment in Health Care, online erschienen am 21.07.2025. Verfasst von Malaisamy Muniyandi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Economics, ICMR-National Institute for Research in Tuberculosis, Chennai, India. Hauptthemen laut MEDLINE: Tuberculosis, Multidrug-Resistant, Antitubercular Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Short-course regimens are currently explored to improve multidrug-resistant tuberculosis effects, reduce costs, as well as enhance patient adherence. Currently, we are determining the most cost-effective shorter regimen out of seven short-course regimens (6–9 months) to treat drug-resistant tuberculosis (DR-TB) compared to the current standard of care (SoC) 9- to 11-month regimen.

Methods

Cost-effectiveness of various short-course DR-TB treatment regimens, namely BEAT, BPaL, BPaLM, BPaLC, mBPaL1, mBPaL2, and mBPaL3, was compared to the current SoC in India. Decision tree model was used from a health system perspective. The information on various costs – such as preinvestigations, regimens, adverse drug reactions (ADRs) management, inpatient treatment – and on effect – such as clinical outcomes and ADRs – was collected from different published sources. It estimated costs, quality-adjusted life years, and incremental cost-effectiveness ratios (ICERs). Sensitivity analyses were performed to validate outcomes against the willingness-to-pay threshold.

Results

When all the short-course regimens were compared with the current SoC regimen, the ICERs were ₹5,385, ₹2,014, ₹2,008, ₹2,435, ₹1,462, ₹1,159, and ₹1,895 for BEAT, BPaL, BPaLM, BPaLC, mBPaL1, mBPaL2, and mBPaL3, respectively. Among the short-course regimens, mBPaL2 is the dominant strategy, and mBPaL1 has extended dominance. For all Bedaquiline-containing regimens, the cost of the drug is a crucial factor in determining cost effectiveness. The cost-effectiveness acceptability curve showed that all shorter regimens were 100 percent cost-effective.

Conclusion

The implementation of Bedaquiline-based regimen to treat DR-TB has become more effective, shorter in duration, and less burdensome to the health system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis, Multidrug-ResistantAntitubercular AgentsCost-Benefit AnalysisHumansIndiaQuality-Adjusted Life YearsDecision TreesDrug Administration Schedule

Stichwörter der Autor:innen

BEATBPaLBPaLCBPaLMDR-TBTBcost-effectivenessmBPaLshorter regimen

Substanzen

Antitubercular Agents

Autor:innen und Institutionen

  • Department of Health Economics, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
  • Department of Clinical Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
  • iDFFEAT TB Project, https://ror.org/037x4qk98International Union Against Tuberculosis and Lung Disease, New Delhi, India.

ORCID-Profile: Malaisamy Muniyandi

Zitieren

APA

Muniyandi, M., Ramraj, B., Vadamalai, S., Abdul Salam, S., Devaleenal, B., Jaju, J., & Padmapriyadarsini, C. (2025). Comparing cost-effectiveness of short-course regimens for drug-resistant tuberculosis treatment in India. International Journal of Technology Assessment in Health Care, 41(1). https://doi.org/10.1017/s0266462325100329

Vancouver

Muniyandi M, Ramraj B, Vadamalai S, Abdul Salam S, Devaleenal B, Jaju J, et al. Comparing cost-effectiveness of short-course regimens for drug-resistant tuberculosis treatment in India. International Journal of Technology Assessment in Health Care. 2025;41(1). doi:10.1017/s0266462325100329

BibTeX
@article{Muniyandi2025,
  author = {Muniyandi, Malaisamy and Ramraj, Balaji and Vadamalai, Sathishkumar and Abdul Salam, Sahil and Devaleenal, Bella and Jaju, Jyoti and Padmapriyadarsini, Chandrasekaran},
  title = {Comparing cost-effectiveness of short-course regimens for drug-resistant tuberculosis treatment in India},
  journal = {International Journal of Technology Assessment in Health Care},
  year = {2025},
  volume = {41},
  number = {1},
  doi = {10.1017/s0266462325100329}
}
Kostenlos starten →